Anal Squamous Cell Carcinoma
18
6
7
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
2 terminated out of 18 trials
75.0%
-11.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Adaptive Radiation in Anal Cancer
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
High Resolution Anuscopy Study
PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
Vectibix for the Treatment of Anal Cancer
Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays
Oral Rigosertib for Squamous Cell Carcinoma
A Phase 1 Study in Participants With Advanced Cancer